Why the study?
Does sulfinpyrazone alter transmembrane action potential characteristics or effective refractory period in isolated canine cardiac Purkinje fibers?
Does sulfinpyrazone alter transmembrane action potential characteristics or effective refractory period in isolated canine cardiac Purkinje fibers?
Sulfinpyrazone does not exhibit direct electrophysiological actions comparable to conventional antiarrhythmic drugs in canine cardiac Purkinje fibers.
No direct EP effects on canine Purkinje fibers; leaves open non-EP mechanisms for reported post-MI sudden death reduction.
Sulfinpyrazone, administered prophylactically following myocardial infarction, has been reported to reduce the incidence of sudden death. Because direct antiarrhythmic action may, in part, account for this finding, electrophysiological effects of sulfinpyrazone were studied in isolated superfused canine cardiac Purkinje fibers. Using conventional microelectrode recording techniques and programmed electrical stimulation, transmembrane action potential (AP) characteristics and effective refractory period (ERP) were determined in seven experiments under control conditions and during sequential 30-min periods of tissue exposure to 10 −6 , 10 −5 , and 10 −4 M sulfinpyrazone (pacing cycle lengths 1000 and 500 ms). In six out of seven experiments, recordings were repeated during a 30- to 45-min drug-free recovery period. In four additional experiments, spontaneously depolarizing Purkinje fibers with low resting membrane potentials (−55 to −65 mV) were superfused with 10 −4 M sulfinpyrazone for 45 min following a drug-free control period. AP resting potential, rate of rise of AP phase 0, AP duration, and ERP were not altered significantly from control or recovery values by sulfinpyrazone exposure. Similarly, neither the AP phase 4 slope nor the mean cycle length (678 ± 32 ms vs. control 665 ± 20 ms, N = 4) of spontaneously firing Purkinje fibers was affected by drug. Thus, sulfinpyrazone did not exhibit direct electrophysiological actions comparable to those associated with conventional antiarrhythmic drugs.
No takes yet. Share an insight, caveat, or question.
Benditt et al. (1980) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: